Keywords:
lacidipine, lacidipine’s R&D Progress, Mechanism of Action for lacidipine, drug target for lacidipine.
Description:
This article summarized the latest R&D progress of lacidipine, the Mechanism of Action for lacidipine, and the drug target R&D trends for lacidipine.
Text:
lacidipine‘s R&D Progress
Lacidipine is a small molecule drug that falls under the therapeutic area of cardiovascular diseases. It specifically targets Cav2.1, a calcium channel subtype involved in regulating blood pressure. The drug is primarily indicated for the treatment of hypertensio.
Lacidipine has reached the highest phase of development which is approved globally. The drug was first approved in Italy in January 1991, marking its initial entry into the market.
As a small molecule drug, Lacidipine is designed to interact with specific molecular targets in the body, in this case, Cav2.1 calcium channels. By modulating the activity of these channels, Lacidipine aims to regulate calcium influx into cells, ultimately leading to the relaxation of blood vessels and a reduction in blood pressure. This mechanism of action makes Lacidipine an effective treatment option for hypertension.
The approval of Lacidipine in multiple countries, including China, highlights its global recognition and acceptance as a safe and effective medication for managing hypertension. Its long history of use since 1991 further demonstrates its established position in the pharmaceutical market.
Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
Mechanism of Action for lacidipine: Cav2.1 inhibitors
Cav2.1 inhibitors are a type of drugs that specifically target and inhibit the activity of the Cav2.1 calcium channels. These channels, also known as P/Q-type calcium channels, are found in the central nervous system and play a crucial role in regulating neurotransmitter release.
From a biomedical perspective, Cav2.1 inhibitors are of interest in the field of neuroscience and neurology. By blocking the activity of Cav2.1 channels, these inhibitors can modulate the release of neurotransmitters such as glutamate, which is involved in neuronal signaling. This modulation can have therapeutic implications for various neurological disorders, including epilepsy, migraine, and ataxia.
Cav2.1 inhibitors can be used as a potential treatment strategy to reduce excessive neuronal excitability and prevent the abnormal release of neurotransmitters. By targeting Cav2.1 channels, these inhibitors can help restore the balance of neurotransmission and alleviate symptoms associated with neurological disorders.
It’s important to note that Cav2.1 inhibitors are still under investigation and development, and their clinical use is not yet widespread. Further research is needed to fully understand their efficacy, safety, and potential side effects before they can be widely prescribed as therapeutic agents.
Drug Target R&D Trends for lacidipine
Cav2.1, also known as P/Q-type calcium channels, plays a crucial role in the human body. These channels are primarily found in the central nervous system and are responsible for regulating the release of neurotransmitters. By controlling the influx of calcium ions into neurons, Cav2.1 channels contribute to the transmission of signals between nerve cells, ultimately influencing various physiological processes such as muscle contraction, hormone secretion, and synaptic plasticity. Dysregulation or dysfunction of Cav2.1 channels has been associated with neurological disorders like epilepsy, ataxia, and migraine. Understanding the role of Cav2.1 channels provides valuable insights for the development of therapeutic interventions targeting these channels to treat related disorders.
According to Patsnap Synapse, as of 6 Sep 2023, there are a total of 15 Cav2.1 drugs worldwide, from 46 organizations, covering 16 indications, and conducting 549 clinical trials.
Based on the analysis of the provided data, the current competitive landscape of target Cav2.1 in the pharmaceutical industry is characterized by the involvement of various companies, with Bayer AG, LTL Pharma Co., Ltd., and CHIESI Farmaceutici SpA leading in terms of drug development. The most common indication for approved drugs targeting Cav2.1 is hypertension, indicating the potential of these drugs in treating cardiovascular disorders. Small molecule drugs are the primary focus in the development of Cav2.1-targeting drugs. China, the European Union, Japan, and the United States are the leading countries/locations in terms of drug development, with China showing significant progress. Overall, the analysis suggests a promising future for the development of drugs targeting Cav2.1 in the pharmaceutical industry.Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target
Conclusion
In summary, Lacidipine is a small molecule drug that targets Cav2.1 calcium channels and is primarily used for the treatment of hypertension. It has achieved approval in multiple countries, including China, and was first approved in Italy in 1991. This information provides a factual overview of Lacidipine’s key characteristics and its significance in the field of biomedicine.
